샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514212

바이오엔지니어링 단백질 의약품 시장

Bioengineered Protein Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오엔지니어링 단백질 의약품 시장은 2030년까지 3,299억 달러에 도달할 것으로 예측됩니다.

2023년에 2,455억 달러로 평가된 바이오엔지니어링 단백질 의약품 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 4.3%로 성장하여 2030년에는 3,299억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 치료용 단백질은 복합 연간 성장률(CAGR) 3.9%로 성장을 지속하고, 분석 기간 종료 시 1,292억 달러에 달할 것으로 예상됩니다. 단클론항체 분절의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 4.3%로 추정됩니다.

미국 시장은 662억 달러로 추정되며 중국은 복합 연간 성장률(CAGR) 7.2%로 성장할 것으로 예측됩니다.

미국의 바이오엔지니어링 단백질 의약품 시장은 2023년 662억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 694억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR) 7.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 1.2%와 4.9%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 2.1%로 성장할 것으로 예측됩니다.

바이오엔지니어링 단백질 의약품 - 주요 동향 및 촉진요인

바이오 의약품으로도 알려진 바이오엔지니어링 단백질 의약품은 의료 부문에 혁명을 일으키고 다양한 질병에 대항하여 효과적인 치료를 제공합니다. 이러한 의약품은 첨단 유전 공학 기술을 사용하여 개발되어 인체에 자연적으로 존재하는 단백질과 동일한 단백질을 생산할 수 있습니다. 이러한 단백질은 특정 생물학적 경로와 상호작용하도록 설계될 수 있어 질병 메커니즘에 대한 정확한 개입을 가능하게 합니다. 예를 들면, 암 치료에 사용되는 단클론항체나, 당뇨병 관리를 위한 인슐린 아날로그 등입니다. 재조합 DNA 기술과 엄격한 정제 공정을 통한 개발의 복잡성은 높은 특이성과 효능을 보장하며 기존의 저분자 의약품과는 획일적입니다. 그 결과, 바이오엔지니어링 단백질 의약품은 류마티스 관절염, 다발성 경화증, 각종 암 등의 만성 질환의 치료의 요점이 되고 있습니다.

바이오엔지니어링 단백질 의약품의 규제 상황은 그 생물학적 기원과 복잡성으로부터 안전성과 효능을 확보할 필요성을 반영하여 엄격해지고 있습니다. 승인 과정에는 일반적으로 부작용과 장기 결과를 모니터링하기 위한 대규모 임상시험과 시판후 조사가 포함됩니다. CRISPR 및 기타 유전자 편집 도구와 같은 생명 공학 혁신은 이러한 의약품의 개발을 더욱 가속화하고, 보다 정확한 수정을 가능하게 하고, 개발 기간을 단축시킬 수 있습니다. 게다가 바이오프로세스와 제조기술의 진보로 생체공학적으로 변형된 단백질을 생산하는 확장성과 비용효과가 향상되고 있습니다.

바이오엔지니어링 단백질 의약품 시장의 성장은 기술의 진보, 만성 질환의 유병률 증가, 개인화된 의료 수용 및 수요 증가 등 여러 요인에 의해 야기됩니다. 기술 혁신에 의해 의약품 개발 프로세스가 합리화되어 비용과 시장 개척 기간이 단축되는 한편, 바이오 의약품 기업은 이러한 진보를 활용하여 보다 강력하고 치밀한 치료를 개발하고 있습니다. 또한 암, 당뇨병, 자가면역질환 등 만성질환의 이환율 상승도 이러한 첨단치료에 대한 수요를 높이고 있습니다. 게다가, 소비자의 행동 동향은 개인화된 의료에 대한 강한 선호도를 보여주며, 생물 공학 단백질은 개인의 유전자 프로파일에 맞출 수 있기 때문에 이를 실현하는데 있어서 독자적인 지위를 차지합니다. 또한 많은 지역에서 유리한 규제 정책과 의료 자금 증가가 시장의 급속한 확대를 지원합니다. 관민 양부문에 의한 연구개발에 대한 투자도 매우 중요하며, 지속적인 기술 혁신과 차세대 바이오의약품의 채용을 뒷받침하고 있습니다.

조사 대상 기업 예(주목의 56사)

  • Abbott India Ltd.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • Dr. Reddys Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Panacea Biotec Ltd.
  • ProBioGen AG

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global Bioengineered Protein Drugs Market to Reach US$329.9 Billion by 2030

The global market for Bioengineered Protein Drugs estimated at US$245.5 Billion in the year 2023, is expected to reach US$329.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Therapeutic Proteins, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$129.2 Billion by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$66.2 Billion While China is Forecast to Grow at 7.2% CAGR

The Bioengineered Protein Drugs market in the U.S. is estimated at US$66.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$69.4 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Bioengineered Protein Drugs - Key Trends and Drivers

Bioengineered protein drugs, also known as biopharmaceuticals, have revolutionized the field of medicine, offering targeted and effective treatments for a wide range of diseases. These drugs are developed using advanced genetic engineering techniques that allow for the production of proteins identical to those naturally occurring in the human body. These proteins can be designed to interact with specific biological pathways, enabling precise intervention in disease mechanisms. Examples include monoclonal antibodies, used in cancer therapy, and insulin analogs for diabetes management. The complexity of their development, involving recombinant DNA technology and rigorous purification processes, ensures high specificity and efficacy, distinguishing them from traditional small-molecule drugs. As a result, bioengineered protein drugs have become a cornerstone in treating chronic conditions such as rheumatoid arthritis, multiple sclerosis, and various types of cancers.

The regulatory landscape for bioengineered protein drugs is stringent, reflecting the need for ensuring safety and efficacy given their biological origin and complexity. The approval process typically involves extensive clinical trials and post-marketing surveillance to monitor adverse effects and long-term outcomes. Innovations in biotechnology, such as CRISPR and other gene-editing tools, have further accelerated the development of these drugs, enabling more precise modifications and potentially reducing development times. Moreover, advancements in bioprocessing and manufacturing techniques have improved the scalability and cost-effectiveness of producing bioengineered proteins. As these technologies evolve, the pipeline of bioengineered protein drugs continues to expand, addressing unmet medical needs and offering new hope for patients with previously untreatable conditions.

The growth in the bioengineered protein drugs market is driven by several factors, including technological advancements, increased prevalence of chronic diseases, and growing acceptance and demand for personalized medicine. Technological innovations have streamlined the drug development process, reducing costs and time-to-market, while biopharmaceutical companies are leveraging these advancements to develop more potent and targeted therapies. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders has also heightened the demand for these advanced treatments. Furthermore, consumer behavior trends indicate a strong preference for personalized medicine, which bioengineered proteins are uniquely positioned to deliver due to their ability to be tailored to individual genetic profiles. Additionally, favorable regulatory policies and increased healthcare funding in many regions are supporting the rapid market expansion. Investment in research and development by both private and public sectors is also pivotal, driving continuous innovation and the introduction of next-generation biopharmaceuticals.

Select Competitors (Total 56 Featured) -

  • Abbott India Ltd.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Panacea Biotec Ltd.
  • ProBioGen AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bioengineered Protein Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Genetic Engineering Propel Growth in Bioengineered Protein Drugs Market
    • Increasing Prevalence of Chronic Diseases Expands Addressable Market Opportunity
    • Personalized Medicine Trends Strengthen Business Case for Bioengineered Proteins
    • Innovations in Bioprocessing Technologies Drive Cost-Efficiency and Scalability
    • Rising Consumer Demand for Targeted Therapies Generates Opportunities
    • Adoption of CRISPR and Gene-Editing Tools Accelerates Development Timelines
    • Healthcare Funding Increases Propel Market Adoption
    • Enhanced Purification Techniques Improve Drug Safety and Efficacy
    • Advanced Manufacturing Technologies Enhance Production Capabilities
    • Post-Marketing Surveillance Strengthens Confidence in Bioengineered Protein Drugs
    • Technological Synergies with Digital Health Tools Enhance Treatment Outcomes
    • Novel Drug Delivery Systems Expand Therapeutic Applications
    • Data Analytics and AI Integration Improve Drug Development Efficiency
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bioengineered Protein Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Therapeutic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Academics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • JAPAN
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • CHINA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • EUROPE
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • FRANCE
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • GERMANY
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • INDIA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Bioengineered Protein Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Bioengineered Protein Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • AFRICA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제